Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer

EJNMMI Research

Table 2 Kinetic clearance parameters for patients

Patient #	1	2	3	4	5	6	7	8	9	10	Mean	SD
WB A ₁	0.67	0.89	0.86	0.70	0.80	0.50	0.67	0.28	0.71	0.67	0.67	0.18
WB a ₁ (h^-1)	0.29	0.24	0.38	1.11	0.45	2.10	0.53	0.89	0.52	0.98	0.75	0.56
WB A ₂	0.33	0.11	0.14	0.30	0.20	0.50	0.33	0.72	0.29	0.33	0.33	0.18
WB a ₂ (h^-1)	0.06	0.02	0.03	0.06	0.05	0.09	0.08	0.08	0.06	0.10	0.06	0.03
Blood A ₁ (%/l)	5.9	18.7	5.7	2.2	5.1	7.1	3.5	2.5	3.2	2.6	5.7	4.9
Blood a ₁ (h^-1)	5.1	6.5	5.8	0.8	1.3	5.6	0.7	1.4	0.8	1.0	2.9	2.5
Blood A ₂ (%/l)	1.3	2.48	1.2	0.38	0.68	0.88	0.88	1.07	0.74	0.61	1.01	0.58
Blood a ₂ (h^-1)	0.12	0.12	0.13	0.08	0.07	0.45	0.07	0.10	0.09	0.12	0.13	0.11
Gut fraction	0.031	0.030	0.027	0.049	0.037	0.033	0.030	0.050	0.047	0.016	0.03	0.02

Whole-body and blood clearance data were fitted to bi-exponential functions viz A(t) = A ₁ exp(-a ₁ t) + A ₂ exp(-a ₂ t), where t is time in hour. Gut fraction is the estimated fraction of ¹²⁴I-IAZGP present in the intestine at (nominally) 24 h after administration.